KRAS mutations predict response to EGFR inhibitors.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current opinion in pharmacology (Print)

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.coph.2008.06.006PMID 18619559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Determinants of RASistance to anti-epidermal growth factor receptor agents.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

  2007cited by this paper
• KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

  2007cited by this paper
• Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

  2006cited by this paper
• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  2006cited by this paper
• Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

  2006cited by this paper
• EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.

  2006cited by this paper
• Defining clinically relevant molecular subsets of lung cancer

  2006cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.

  1991cited by this paper
• Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products.

  1990cited by this paper
• Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

  1988cited by this paper

• Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

  2026cites this paper
• Research hotspots and emerging trends in targeted therapy for colorectal cancer: a bibliometric analysis (2000–2023)

  2025cites this paper
• Treatment Strategies’ Impact on Progression-Free Survival According to RMST Function in Metastatic Colorectal Cancer Patients: A Retrospective Study from Romania

  2024cites this paper
• Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

  2024cites this paper
• Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers

  2024cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• Мутации в генах KRAS/NRAS и эффективность индукционной терапии по трехкомпонентным схемам на основе бортезомиба у пациентов с впервые диагностированной множественной миеломой

  2024cites this paper
• KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas

  2023cites this paper
• Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities

  2023cites this paper
• How to create value with constrained budgets in oncological care? A narrative review

  2023cites this paper
• Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy

  2022influential citation
• A novel DNA damage repair-related signature for predicting prognositc and treatment response in non-small lung cancer

  2022cites this paper
• Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data

  2022influential citation
• Advancing precision oncology with large, real-world genomics and treatment outcomes data

  2022cites this paper
• Prognostic and predictive biomarkers in metastatic colorectal cancer constant and evolutionary perspectives

  2021cites this paper
• PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab

  2021cites this paper
• The diverse molecular profiles of lynch syndrome-associated colorectal cancers are (highly) dependent on underlying germline mismatch repair mutations.

  2021cites this paper
• Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis

  2021cites this paper
• Automation of Organoid Cultures: Current Protocols and Applications

  2021cites this paper
• Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients

  2020cites this paper
• NMR in integrated biophysical drug discovery for RAS: past, present, and future

  2020cites this paper
• Realizing Cancer Precision Medicine by Integrating Systems Biology and Nanomaterial Engineering

  2020cites this paper
• NUDT7 Loss Promotes KrasG12D CRC Development

  2020cites this paper
• HB-EGF–EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma

  2020cites this paper
• Probiotics for Management of Gastrointestinal Cancers

  2020cites this paper
• Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

  2019cites this paper
• Exploring the Pharmacological Mechanism of the Herb Pair “HuangLian-GanJiang” against Colorectal Cancer Based on Network Pharmacology

  2019cites this paper
• Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers

  2019influential citation
• Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.

  2019cites this paper
• Association of genetic ancestry with colorectal tumor location in Puerto Rican Latinos

  2019cites this paper
• Detection of gene mutations in gastric cancer tissues using a commercial sequencing panel

  2019influential citation
• Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient.

  2019cites this paper
• RAS-mediated oncogenic signaling pathways in human malignancies.

  2019cites this paper
• KRAS as Potential Target in Colorectal Cancer Therapy

  2019cites this paper
• BRAF Mutation and Its Importance in Colorectal Cancer

  2019cites this paper
• Association Between Patient Characteristics and Diet Profile with Kirsten rat sarcoma Kras and Neuroblastoma rat sarcoma (Nras) Gene Mutation in Colorectal Cancer

  2019cites this paper
• Human Gut Microbiota and Gastrointestinal Cancer

  2018cites this paper
• Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer

  2018cites this paper
• Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers

  2018cites this paper
• Single Nucleotide Polymorphisms as Biomarkers for Drug Response and Toxicity in the Management of Colorectal Cancer

  2018cites this paper
• Associations among histological characteristics and patient outcomes in colorectal carcinoma with a mucinous component

  2018cites this paper
• Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

  2017cites this paper
• Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.

  2016cites this paper
• Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors.

  2016cites this paper
• The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers.

  2016cites this paper
• Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo

  2016cites this paper
• Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer.

  2016cites this paper
• Molecular Mechanisms Regulating MYC and PGC1β Expression in Colon Cancer

  2016influential citation
• Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.

  2016cites this paper
• KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.

  2015cites this paper
• Genetic markers and evolution of targeted therapy in cancer

  2015cites this paper
• Chronic inflammation and the development of malignancy in the GI tract.

  2015cites this paper
• Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy

  2015cites this paper
• In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging

  2015cites this paper
• The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors

  2015cites this paper
• Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors.

  2015cites this paper
• Rapid KRAS Mutation Detection via Hybridization-Induced Aggregation of Microbeads.

  2015cites this paper
• Genetic Markers and Evolution of Targeted Therapy in

  2015cites this paper
• Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.

  2015influential citation
• A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2014cites this paper
• Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.

  2014cites this paper
• Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status

  2014cites this paper
• Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

  2014cites this paper
• Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases

  2014cites this paper
• Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent

  2014cites this paper
• Low Frequency of KRAS Mutation in Pancreatic Ductal Adenocarcinomas in Korean Patients and Its Prognostic Value

  2014cites this paper
• Pathologic Evaluation of Tissues Obtained by Interventional Radiology Techniques

  2014cites this paper
• Synthetic Genistein Glycosides Inhibiting EGFR Phosphorylation Enhance the Effect of Radiation in HCT 116 Colon Cancer Cells

  2014cites this paper
• BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications

  2014cites this paper
• Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.

  2014cites this paper
• Post-Transcriptional Regulation of Connexin43 in H-Ras-Transformed Cells

  2013cites this paper
• The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

  2013cites this paper
• EGFR-TKI在非小细胞肺癌中耐药机制的研究进展

  2013cites this paper
• EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

  2013cites this paper
• Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.

  2013cites this paper
• Respiratory cytology in the era of molecular diagnostics: A review

  2012cites this paper
• GFR mutation testing in non-small cell lung ancer ( NSCLC )

  2012cites this paper
• Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer

  2012cites this paper
• Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

  2012cites this paper
• Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR

  2012cites this paper
• Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

  2012cites this paper
• Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma

  2012cites this paper
• EGFR mutation testing in non-small cell lung cancer (NSCLC).

  2012cites this paper
• Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.

  2012cites this paper
• Synergistic interactions of targeted therapy within signal transduction pathways

  2012cites this paper
• The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.

  2012cites this paper
• Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance

  2011cites this paper
• Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer

  2011cites this paper
• Detection of KRAS mutations in tumor cells using biochips

  2011cites this paper
• 非小细胞肺癌个体化治疗相关分子标记物

  2011cites this paper
• Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

  2011cites this paper
• The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target

  2011cites this paper
• Ras in cancer and developmental diseases.

  2011cites this paper
• Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

  2011cites this paper
• Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer

  2011cites this paper
• Quantifying factors for the success of stratified medicine

  2011cites this paper
• KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

  2010cites this paper
• Targeting Ras for Anticancer Drug Discovery

  2010cites this paper
• Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503

  2010cites this paper
• Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.

  2010cites this paper